KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Kensei Yamaguchi, Hirokazu Shoji, Hisateru Yasui, Eiji Oki, Daisuke Sakai, Tetsuya Hamaguchi, Akihito Tsuji, Takashi Oshima, Masahiro Tsuda, Keiko Minashi, Jianning Yang, Abraham Guerrero, Yoko Ueno, Maria Matsangou, Georgia Gourgioti, Yuka Nakanishi, Satomi Furuki, Kana Kuwamoto, Shunsuke Yamada, Kohei Shitara

Gastric Cancer 29(4) 777-787

PMID42095986
PMCIDPMC13314679
DOI10.1007/s10120-026-01738-7
发表日期2026-05-07
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Zolbetuximab is a monoclonal antibody targeting claudin 18 isoform 2 (CLDN18.2) approved for first-line treatment of CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Here, we report efficacy and safety outcomes from the combined Japanese subgroup analysis of SPOTLIGHT and GLOW. METHODS: Global, double-blind, phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials investigated zolbetuximab plus chemotherapy versus placebo plus chemotherapy in patients with CLDN18.2-positive, HER2-negative, LA unresectable or metastatic gastric or GEJ adenocarcinoma. The primary endpoint in both trials was progression-free survival (PFS); overall survival (OS) was a key secondary endpoint. RESULTS: Of 1072 patients enrolled, 116 Japanese patients (SPOTLIGHT, n = 65; GLOW, n = 51) comprised the combined Japanese subgroup. The baseline characteristics of Japanese patients were generally similar to those of the overall study populations. In the combined Japanese subgroup, PFS was improved with zolbetuximab plus chemotherapy versus placebo plus chemotherapy (20.53 months [95% confidence interval (CI) 12.09-not estimable] versus 8.28 months [95% CI 6.57-9.07]). Median OS was 23.06 months (95% CI 16.49-25.49) in the zolbetuximab group versus 16.53 months (95% CI 10.38-18.33) in the placebo group. No new safety signals were observed. CONCLUSIONS: In Japanese patients, zolbetuximab plus chemotherapy improved PFS versus placebo plus chemotherapy and showed a numerical improvement in OS. These results support zolbetuximab plus chemotherapy as a potential new standard-of-care first-line option for Japanese patients with CLDN18.2-positive, HER2-negative, LA unresectable or metastatic gastric or GEJ adenocarcinoma.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 1

Fig. 1 PFS by IRC in the combined Japanese subgroup. a Kaplan–Meier plot of PFS by treatment group. b Subgroup analyses of PFS by treatment group. CI confidence interval, GEJ gastroesophageal junction, HR hazard ratio, IRC independent review committee, NE not estimable, PFS progression-free survival

Kaplan_Meier_plot_of_PFS_by_treatment_group

PFS

Fig. 1 · Panel Kaplan_Meier_plot_of_PFS_by_treatment_group

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan_Meier_plot_of_PFS_by_treatment_group 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 2

Fig. 2 OS in the combined Japanese subgroup. a Kaplan–Meier plot of OS by treatment group. b Subgroup analyses of OS by treatment group. CI confidence interval, GEJ gastroesophageal junction, HR hazard ratio, NE not estimable, OS overall survival

A

OS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

KM endpoint

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 3Fig. 3 Adverse events in >10% of patients in either treatment group in the combined Japanese subgroup safety analysis set. a Chemotherapy was either mFOLFOX6 (SPOTLIGHT) or CAPOX (GLOW). ALT alanine aminotransferase, AST aspartate aminotransferase, CAPOX capecitabine and oxaliplatin, mFOLFOX6 modified folinic acid (or levofolinate), fluorouracil, and oxaliplatin
非 KM Figure